Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Background A previous randomized phase II study demonstrated that the addition of a c-Met
inhibitor tivantinib to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …

Background We conducted a randomized, placebo-controlled, double-blind trial to
determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …